Detalhe da pesquisa
1.
The OPTIFAST total and partial meal replacement programme reduces cardiometabolic risk in adults with obesity: Secondary and exploratory analysis of the OPTIWIN study.
Diabetes Obes Metab
; 26(3): 950-960, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38073426
2.
Females with type 2 diabetes are at higher risk for accelerated cognitive decline than males: CAROLINA-COGNITION study.
Nutr Metab Cardiovasc Dis
; 32(2): 355-364, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34895804
3.
Effects of linagliptin vs glimepiride on cognitive performance in type 2 diabetes: results of the randomised double-blind, active-controlled CAROLINA-COGNITION study.
Diabetologia
; 64(6): 1235-1245, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33559704
4.
Empagliflozin treatment effects across categories of baseline HbA1c, body weight and blood pressure as an add-on to metformin in patients with type 2 diabetes.
Diabetes Obes Metab
; 23(2): 425-433, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33084149
5.
Impact of polyvascular disease with and without co-existent kidney dysfunction on cardiovascular outcomes in diabetes: A post hoc analysis of EMPA-REG OUTCOME.
Diabetes Obes Metab
; 23(5): 1173-1181, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33502090
6.
Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: A subgroup analysis of the randomized CAROLINA trial.
Diabetes Obes Metab
; 23(2): 569-580, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33185002
7.
Effect of empagliflozin on cardiorenal outcomes and mortality according to body mass index: A subgroup analysis of the EMPA-REG OUTCOME trial with a focus on Asia.
Diabetes Obes Metab
; 23(8): 1886-1891, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33950573
8.
Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOME® trial.
Eur Heart J
; 41(2): 209-217, 2020 01 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31504427
9.
Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial.
Circulation
; 139(11): 1384-1395, 2019 03 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30586757
10.
Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA.
Circulation
; 139(3): 351-361, 2019 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30586723
11.
Cardiovascular and kidney outcomes of linagliptin treatment in older people with type 2 diabetes and established cardiovascular disease and/or kidney disease: A prespecified subgroup analysis of the randomized, placebo-controlled CARMELINA® trial.
Diabetes Obes Metab
; 22(7): 1062-1073, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32037653
12.
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
N Engl J Med
; 375(4): 323-34, 2016 Jul 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-27299675
13.
Comparison of the associations between non-traditional and traditional indices of adiposity and cardiovascular mortality: an observational study of one million person-years of follow-up.
Int J Obes (Lond)
; 43(5): 1082-1092, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30926954
14.
Asymptomatic coronary artery disease in a Norwegian cohort with type 2 diabetes: a prospective angiographic study with intravascular ultrasound evaluation.
Cardiovasc Diabetol
; 18(1): 26, 2019 03 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30851727
15.
FDA guidance on antihyperglyacemic therapies for type 2 diabetes: One decade later.
Diabetes Obes Metab
; 21(5): 1073-1078, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30690856
16.
Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial.
Eur Heart J
; 39(5): 363-370, 2018 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29020355
17.
Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial.
JAMA
; 322(12): 1155-1166, 2019 Sep 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-31536101
18.
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.
JAMA
; 321(1): 69-79, 2019 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30418475
19.
Empagliflozin in women with type 2 diabetes and cardiovascular disease - an analysis of EMPA-REG OUTCOME®.
Diabetologia
; 61(7): 1522-1527, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29713728
20.
Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin.
Kidney Int
; 93(1): 231-244, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28860019